The Safety and Pharmacokinetics of Primapur and Gonal-f
Status:
Completed
Trial end date:
2016-05-10
Target enrollment:
Participant gender:
Summary
The purpose of the current phase I study was to establish bioequivalence, safety, and
tolerance of single 300 IU subcutaneous dose of follitropin alfa biosimilar (Primapur) in
comparison to that of reference follitropin alfa preparation (Gonal-F) in healthy young
female volunteers.